In today’s rapidly evolving biotechnology and pharmaceutical landscape, High-Throughput Screening (HTS) has emerged as a game-changing technology. It enables scientists to rapidly test thousands to millions of chemical, genetic, or pharmacological samples for biological activity. The demand for HTS is growing exponentially, driven by advances in automation, artificial intelligence (AI), and the increasing need for precision medicine.
According to market projections, the global HTS market is on a robust growth trajectory, set to expand from $23.8 billion in 2024 to $39.2 billion by the end of 2029, with a compound annual growth rate (CAGR) of 10.5%.